Arch Biopartners Inc. is focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. Arch works closely with the scientific community, universities and research institutions to advance and build the value of select preclinical technologies, develop the most promising intellectual property, and create value for its investors.
Arch has established a diverse portfolio that includes:
Metablok™, a potential treatment for inflammation, sepsis and cancer metastasis;
AB569, a potential new treatment for antibiotic resistant bacterial infections;
‘Borg’ peptide coatings that increase corrosion resistance and decrease biofilm on various medical grade metals and plastics; and,
MetaMx™, which targets elusive brain tumor initiating cells.
Arch has established a diverse portfolio that includes:
Metablok™, a potential treatment for inflammation, sepsis and cancer metastasis;
AB569, a potential new treatment for antibiotic resistant bacterial infections;
‘Borg’ peptide coatings that increase corrosion resistance and decrease biofilm on various medical grade metals and plastics; and,
MetaMx™, which targets elusive brain tumor initiating cells.
Location: Canada, Ontario, Toronto
Employees: 11-50
Founded date: 2010
Investors 1
| Date | Name | Website |
| - | Innovate C... | innovateca... |
Mentions in press and media 4
| Date | Title | Description |
| 07.03.2024 | Arch Biopartners Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury | - |
| 27.06.2023 | Arch Biopartners Receives Permission From U.S. FDA to Proceed With Phase II Acute Kidney Injury Trial | Approval from FDA to initiate Phase II trial with LSALT peptide to target cardiac surgery-associated acute kidney injury (CS-AKI) LSALT peptide targets dipeptidase-1 (DPEP-1), an enzyme known to mediate organ inflammation in the lungs, live... |
| 15.12.2020 | Westlake Village BioPartners Launches Two New Funds Totaling $500 Million to Advance Transformative Treatments | |
| 15.12.2020 | Westlake Village BioPartners Raises $500M In Two Funds | Los Angeles-based life sciences investor Westlake Village BioPartners announced today that it has raised two new venture capital funds, worth a total of $500M, for its investments in biotech companies. According to the company, its two fund... |